China NMPA Inspection - National Medical Products Administration - June 29, 2021

The Jiangxi Provincial Drug Administration issued Announcement No. [2021] 33 on June 29, 2021, detailing follow-up supervisory inspections conducted on 10 cosmetics manufacturers. These inspections took place between March and June 2021, with the primary objective of compelling enterprises to fully uphold their fundamental responsibilities for product quality and safety, thereby ensuring the integrity of cosmetics production within the province. While the provided document does not list specific violations or deficiencies uncovered during these inspections, it clearly indicates that a comprehensive summary table, contained in an attached Excel file, provides these details. The overarching regulatory framework for these activities is the provincial implementation of national cosmetic supervision and administration standards, which mandate stringent oversight to safeguard public health and consumer interests. The required actions stemming from these inspections universally call upon manufacturing enterprises to rigorously implement and maintain their primary responsibility for quality control and product safety. This initiative by the Jiangxi Provincial Drug Administration underscores a proactive approach to regulatory enforcement, designed to identify and rectify any non-compliance with established cosmetic production guidelines and to continuously improve quality management systems across the industry.